DNA Test Could Spare Millions of Breast Cancer Patients From Chemotherapy

An international team of researchers has developed a DNA screening tool that could allow millions of breast cancer patients to skip chemotherapy without harming their chances of survival, according to results from a major clinical trial.

The genetic test works by analyzing tumor DNA to predict which patients face high enough recurrence risk to warrant chemotherapy and which ones can safely forgo the treatment. Doctors have long struggled to identify this distinction, often erring on the side of recommending chemotherapy even when patients might recover without it.

Chemotherapy remains one of the most aggressive cancer treatments. It carries significant side effects including hair loss, nausea, fatigue, and long-term complications such as heart damage and secondary cancers. Patients frequently endure months of treatment cycles, which can interfere with work, family life, and overall quality of life.

The trial enrolled patients across multiple countries and institutions, making it one of the largest efforts to validate such a screening approach. Researchers followed patients over time to track recurrence rates and survival outcomes between those who received chemotherapy and those who did not, based on their genetic profiles.

The findings suggest that clinicians could use the DNA test to tailor treatment decisions more precisely, aligning recommendations with individual patient risk factors rather than applying a uniform approach to all diagnoses.

Oncologists have increasingly turned to genetic testing in recent years as a way to personalize cancer care. The practice reflects a broader shift in medicine toward analyzing a patient's specific tumor characteristics rather than treating all cancers of the same type identically.

Breast cancer remains the most common cancer among women globally. In the United States alone, doctors diagnose more than 280,000 new cases annually. Not all patients require chemotherapy, but distinguishing who benefits from it and who does not has proven difficult using traditional diagnostic methods.

The researchers did not specify the exact percentage of patients who could potentially avoid chemotherapy based on the test results, nor did they detail the test's cost or availability timeline. Additional implementation steps likely remain before widespread adoption in clinical practice.

Oncologists and patient advocacy groups have emphasized the importance of such tools in reducing unnecessary treatment burden. However, doctors cautioned that genetic testing should complement rather than replace other diagnostic factors, including tumor stage, grade, and patient age and health status.

The study represents one of several ongoing efforts to refine which patients truly need chemotherapy. Other research teams have pursued similar genetic screening strategies, though results and methodologies vary across trials.